Special Issue "Antioxidant and Anti-Inflammatory Agents in Chronic Liver Diseases"
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 127
2. NextGen Precision Health Institute, University of Missouri, Columbia, MO 65212, USA
3. Harry S. Truman Memorial VA Hospital, Columbia, MO 65201, USA
Interests: chronic liver disease; non-alcoholic fatty liver disease; hepatocellular carcinoma; inflammation; oxidative stress; natural products; treatment; anticancer peptides
Special Issues, Collections and Topics in MDPI journals
Chronic liver diseases (CLD) include alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), chronic viral infection, autoimmune hepatitis, etc., which may lead to liver fibrosis, cirrhosis, and cancer. Currently, there are no effective treatments for ALD-induced liver cancer. Liver inflammation, oxidative stress, and cell death are commonly associated with the progression of CLD. Recent studies have shown that anti-inflammatory and antioxidant agents are promising therapies against CLD. In addition, metabolic dysfunctions such as lipid accumulation and insulin resistance are commonly associated with CLD-to-cancer progression, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Therefore, it is essential to understand the underlying molecular and metabolic signaling pathways involved in the pathogenesis of CLD and target these pathways to develop therapeutic strategies to ameliorate CLD. This Special Issue, entitled “Antioxidant and Anti-Inflammatory Agents in Chronic Liver Diseases”, aims to provide a comprehensive overview of the most recent advances in this field and explore the current options and future research directions for CLD studies.
Dr. Ming Yang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic liver disease
- non-alcoholic fatty liver disease
- alcoholic liver disease
- liver inflammation
- oxidative stress
- liver fibrosis
- hepatocellular carcinoma